Tarzian Martin, Ndrio Mariana, Chique Byron, Serai Japjit, Thalackal Bryce, Lau Jessi, Fakoya Adegbenro O
Psychiatry, University of Medicine and Health Sciences, Basseterre, KNA.
Psychiatry and Behavioral Sciences, University of Medicine and Health Sciences, Basseterre, KNA.
Cureus. 2023 Sep 28;15(9):e46143. doi: 10.7759/cureus.46143. eCollection 2023 Sep.
This drug review provides a comprehensive analysis of a novel antipsychotic called lumateperone, marketed as Caplyta. Lumateperone gained FDA approval in 2019 for treating schizophrenia and later, in 2021, for treating bipolar depression. The review begins by delving into lumateperone's mechanism of action, which involves the partial agonism of the dopamine D2 receptor as well as its unique effects on the dopamine transporter, N-methyl-D-aspartate (NMDA) receptor, and serotonin transporter. Additionally, the study examines lumateperone's distinctive pharmacokinetics. Moreover, this review assesses lumateperone's metabolic profile and highlights its favorable outcomes regarding mean body weight, BMI, and waist circumference, surpassing those of other second-generation antipsychotic medications. The study explicitly emphasizes the efficacy and safety of lumateperone in treating schizophrenia and bipolar depression associated with bipolar I and II disorders. An extensive investigation of multiple clinical trials provides compelling evidence of lumateperone's advantages over existing antipsychotic medications. The review also acknowledges the limitations of lumateperone compared to other antipsychotics. In conclusion, this drug review underscores the importance of further research to uncover the additional limitations of lumateperone while acknowledging its promising benefits and potential for advancing treatment options.
本药物综述对一种名为鲁马哌酮（商品名：Caplyta）的新型抗精神病药物进行了全面分析。鲁马哌酮于2019年获得美国食品药品监督管理局（FDA）批准用于治疗精神分裂症，随后在2021年获批用于治疗双相抑郁。该综述首先深入探讨了鲁马哌酮的作用机制，包括其对多巴胺D2受体的部分激动作用以及对多巴胺转运体、N-甲基-D-天冬氨酸（NMDA）受体和5-羟色胺转运体的独特作用。此外，该研究还考察了鲁马哌酮独特的药代动力学。而且，本综述评估了鲁马哌酮的代谢特征，并强调了其在平均体重、体重指数（BMI）和腰围方面的良好结果，优于其他第二代抗精神病药物。该研究明确强调了鲁马哌酮在治疗与I型和II型双相情感障碍相关的精神分裂症和双相抑郁方面的疗效和安全性。对多项临床试验的广泛调查提供了令人信服的证据，证明鲁马哌酮优于现有的抗精神病药物。该综述也承认了鲁马哌酮与其他抗精神病药物相比存在的局限性。总之，本药物综述强调了进一步研究的重要性，以揭示鲁马哌酮的其他局限性，同时认可其有前景的益处和推进治疗选择的潜力。
